FDA Approved: EDARBYCLOR — Supplemental Application (Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals))

View source ↗

Summary

The FDA approved a supplemental application for EDARBYCLOR, the fixed-dose combination of azilsartan medoxomil and chlorthalidone, developed by Azurity Pharmace…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• EDARBYCLOR (AZILSARTAN KAMEDOXOMIL AND CHLORTHALIDONE)

Snippet

SUPPL AP for EDARBYCLOR (AZILSARTAN KAMEDOXOMIL AND CHLORTHALIDONE)